Key result
Within-class discharge drug choices show no significant difference in 3-month major cardiovascular events after ACS.
Why the study?
Do specific individual agents within guideline-directed discharge medication classes (ticagrelor vs. clopidogrel, empagliflozin vs. dapagliflozin, ACEI vs. ARB/ARNI, 3rd-gen vs. 2nd-gen beta-blockers, rosuvastatin vs. atorvastatin) reduce 3-month MACE in older patients aged ≥60 years with acute coronary syndrome and multivessel coronary disease?
Cohort (n=277)
Yes
Do specific individual agents within guideline-directed discharge medication classes (ticagrelor vs. clopidogrel, empagliflozin vs. dapagliflozin, ACEI vs. ARB/ARNI, 3rd-gen vs. 2nd-gen beta-blockers, rosuvastatin vs. atorvastatin) reduce 3-month MACE in older patients aged ≥60 years with acute coronary syndrome and multivessel coronary disease?
Answers are grounded in this paper and cite their sources.
In older patients with acute coronary syndrome and multivessel coronary disease, core secondary prevention pharmacotherapy was widely implemented at discharge, and within-class agent comparisons showed no statistically significant differences in 3-month MACE after adjustment.
Background Guideline-directed medical therapy is central to secondary prevention after acute coronary syndrome (ACS), but recommendations are usually framed at the medication-class level. In discharge practice, clinicians must select individual agents, especially in older patients with multivessel coronary disease. This study described discharge prescribing patterns and examined associations between within-class medication choices and short-term major adverse cardiovascular events (MACE). Methods This prospective, multicenter, real-world observational cohort included 277 patients aged ≥60 years with ACS and multivessel coronary disease. The primary outcome was 3-month MACE. Risk ratios (RRs) were estimated using modified Poisson regression with robust standard errors. Results Core secondary prevention therapies were frequently prescribed, including dual antiplatelet therapy in 99.3% and statins in 99.6%. In fully adjusted within-class analyses, ticagrelor versus clopidogrel had an RR of 0.70 for short-term MACE (95% CI, 0.40–1.21; P = 0.203), empagliflozin versus dapagliflozin had an RR of 1.55 (95% CI, 0.93–2.59; P = 0.094), and rosuvastatin versus atorvastatin had an RR of 1.21 (95% CI, 0.79–1.85; P = 0.372). Exploratory subgroup analyses showed nominal signals for ticagrelor versus clopidogrel among patients with frailty (RR, 0.36; 95% CI, 0.15–0.89; P = 0.026), and for empagliflozin versus dapagliflozin among patients with left ventricular ejection fraction <50% (RR, 1.86; 95% CI, 1.07–3.21; P = 0.027) and non-ST-segment elevation acute coronary syndrome (RR, 2.26; 95% CI, 1.05–4.88; P = 0.037). However, none remained statistically significant after adjustment for multiple comparisons. Conclusions In older patients with ACS and multivessel disease, secondary prevention was widely implemented. Within-class comparisons showed no clear short-term MACE differences, while subgroup signals require validation.
No takes yet. Share an insight, caveat, or question.
Dang et al. (2026) conducted a cohort in Acute coronary syndrome and multivessel coronary disease (n=277). Ticagrelor (within-class discharge medication comparison) vs. Clopidogrel was evaluated on 3-month major adverse cardiovascular events (MACE: composite of all-cause death, recurrent MI, stroke, hospitalization for heart failure, hospitalization for unstable angina, or unplanned repeat PCI) (RR 0.70, 95% CI 0.40-1.21, p=0.203). Within-class discharge comparisons showed no significant differences in 3-month major cardiovascular events in older patients with ACS and multivessel disease.
Synapse has enriched 10 related papers. Consider them for comparative context: